Manipal Health

Manipal Health Enterprises Limited is a leading name in the Indian healthcare landscape, operating as part of the renowned Manipal Group, which was established by T. M. A. Pai. The company has evolved into a comprehensive healthcare provider, integrating tertiary care hospitals with primary care clinics and diagnostic facilities to ensure a continuum of care for its patients.

The company's business model focuses on providing high-quality medical services across a wide array of specializations. Its core offerings include complex procedures such as organ transplants and advanced treatments in cardiology, oncology, neurology, and orthopaedics, alongside a strong emphasis on preventive healthcare.

In terms of operational scale, as of September 30, 2025, Manipal Health operates 38 hospitals, which expands to 48 hospitals on a pro forma basis. This vast infrastructure comprises 10,761 beds, increasing to 12,367 licensed beds on a pro forma basis, supplemented by 17 operational clinics across its service areas.

The company is driven by a mission to make quality healthcare more accessible and available to the broader population. Its market position is bolstered by its association with the Manipal Group's legacy of educational and professional excellence.

The promoter group consists of Dr. Ranjan Ramdas Pai, Manipal Global Health Services, Memg International Ltd, Kangto Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd., and Kabru Investments Pte. Ltd., providing strong strategic leadership and backing.

The Manipal Health Enterprises IPO is a massive book-build issue with a total size of approximately ₹9,273.64 Crores. The structure is heavily weighted towards growth, consisting of a fresh issue of approximately ₹8,000 Crores and an offer for sale (OFS) of 2,16,13,834 equity shares. The price band is set between ₹560 and ₹590 per share, with a minimum retail lot size of 25 shares requiring an investment of ₹14,750. The issue opens on July 29, 2026, and closes on July 31, 2026, with listing scheduled for August 5, 2026, on the BSE and NSE.

The proceeds from the fresh issue are primarily earmarked for debt reduction and strategic expansion. Specifically, ₹5,378 Crore will be used for the repayment or prepayment of outstanding borrowings and accrued interest of its material subsidiary, Manipal Hospitals Private Limited, while ₹574 Crore is allocated for acquiring a minority stake in its step-down subsidiary, Sahyadri Hospitals Private Limited.

Financial performance shows strong top-line growth, with revenue increasing from ₹6,265.17 Crore in FY24 to ₹8,362.79 Crore in FY25, and reaching ₹10,520.52 Crore in FY26. However, the bottom line has shown inconsistency; PAT surged to ₹1,081.67 Crore in FY25 but dipped to ₹916.52 Crore in FY26, indicating a pressure on margins despite revenue growth.

Valuation-wise, the company reports an EPS of ₹7.71 (Basic) for FY26 and a ROCE of 21.88%. When compared to listed peers like Apollo Hospitals, Fortis Healthcare, and Max Healthcare, the sector generally commands high P/E multiples (ranging from 66x to 74x), suggesting that the healthcare sector's premium remains intact.

Key investment strengths include its massive operational scale, strong brand equity under the Manipal Group, and a significant fresh capital infusion to deleverage the balance sheet. Conversely, the primary risks include the decline in PAT in the most recent fiscal year and the potential for 'absorption drag' given the mega-size of the issue.

Investors should view this IPO as a long-term play in the healthcare infrastructure space. While the scale is impressive, the recent profit dip and the sheer volume of shares being listed may limit the immediate listing pop, making it more suitable for those looking at the fundamental growth of Indian healthcare.